XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
Total
Preferred stock
Common stock
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income (loss)
Non- controlling interest
Beginning balance (in shares) at Dec. 31, 2019   23 101,361,034        
Beginning balance at Dec. 31, 2019 $ 5,404,858 $ 0 $ 101,361 $ 742,646,785 $ (739,785,655) $ 472,608 $ 1,969,759
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock for cash, net of financing costs (in shares)     43,148,952        
Issuance of common stock for cash, net of financing costs 208,241,933   $ 43,149 208,198,784      
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)     1,405,114        
Exercise of stock options for cash and vesting of RSUs, net of tax payments 3,100,703   $ 1,405 3,099,298      
Stock-based compensation 4,001,553     4,017,761     (16,208)
Acquisition of non-controlling interest in Geneos 2,169,998           2,169,998
Net loss attributable to common stockholders (33,135,404)       (32,541,054)   (594,350)
Unrealized gain (loss) on short-term investments, net of tax (1,929,538)         (1,929,538)  
Foreign currency translation 0            
Ending balance (in shares) at Mar. 31, 2020   23 145,915,100        
Ending balance at Mar. 31, 2020 187,854,103 $ 0 $ 145,915 957,962,628 (772,326,709) (1,456,930) 3,529,199
Beginning balance (in shares) at Dec. 31, 2020   9 186,851,493        
Beginning balance at Dec. 31, 2020 461,140,758 $ 0 $ 186,851 1,367,406,869 (906,196,812) (256,150) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock for cash, net of financing costs (in shares)     20,355,000        
Issuance of common stock for cash, net of financing costs 162,105,030   $ 20,355 162,084,675      
Conversion of preferred stock to common stock (in shares)     1,009,450        
Conversion of preferred stock to common stock 4,377,892   $ 1,009 4,376,883      
Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)     1,118,093        
Exercise of stock options for cash and vesting of RSUs, net of tax payments (1,201,789)   $ 1,118 (1,202,907)      
Stock-based compensation 9,595,947     9,595,947      
Net loss attributable to common stockholders (54,402,131)       (54,402,131)    
Unrealized gain (loss) on short-term investments, net of tax 4,861         4,861  
Foreign currency translation (14,419)         (14,419)  
Ending balance (in shares) at Mar. 31, 2021   9 209,334,036        
Ending balance at Mar. 31, 2021 $ 581,606,149 $ 0 $ 209,333 $ 1,542,261,467 $ (960,598,943) $ (265,708) $ 0